Expanded gross sales drive fuels market progress.
IRVINE, CA., January 13, 2023 /OrthoSpineNews/ – HippoFi, Inc. (previously ORHub), (OTC Pink: ORHB), a diversified firm targeted on the biotech and fintech markets, launches 2023 with strong gross sales of its PUR Biologics line of merchandise. “Now we have expanded our gross sales channels within the final 6 weeks by over 28% and anticipate this speedy progress to proceed all year long. Buyer demand is driving gross sales in direction of document highs as we regularly assist sufferers with our superior biologic options. HippoFi’s Biotech division is effectively positioned to be a pacesetter in biologics with our PUR Biologics providing and promising future applied sciences,” mentioned CJ Wiggins, Govt Chairman & CEO of HippoFi, Inc.
“We’re energized by the great assist and optimistic suggestions we’re receiving from our surgeon prospects, strategic companions, and distributor channels. This exponential success in gross sales represents a rising momentum to seize important market share over the following 12 months and is a credit score to our excellent workforce and our distinctive trade relationships,” said Ryan Fernan, Head of PUR Biologics.
HippoFi is traded on the OTC beneath the image “ORHB”.
About HippoFi, Inc.
HippoFi, Inc. delivers its cutting-edge healthcare improvements via an in depth gross sales channel community whereas implementing first-to-market options within the multibillion-dollar Biotech, Fintech, and Synthetic Intelligence (AI) markets. HippoFi contains three segments: Regenerative Therapeutics, Digital Funds, and AI, which make the most of the identical buyer channels to commercialize options, drive income, and enhance affected person outcomes.
PUR Biologics®, HippoFi’s Regenerative Therapeutic division, provides a portfolio of progressive organic merchandise and proprietary applied sciences for bone progress in surgical Backbone procedures in addition to patented bioactive mobile matrix compositions and superior autologous cell therapies for regenerating cartilage in joints and spinal discs.
HippoFi-Pay™, the corporate’s Digital Fee division, operates a surgical implant and enterprise administration software program, which standardize processes on the level of surgical care with improved logistics and efficiencies to offer medical machine and biologic distributors with HIPAA & NPI compliant implant verification and quicker funds.
HippoFi’s AI division is targeted particularly on the usage of AI for early analysis and predictive modeling of Most cancers and enhancing enterprise choices particular to Backbone surgical procedure.
HippoFi, Inc. is publicly traded beneath the image: ORHB and is headquartered in Irvine, California. For extra data, please go to: www.HippoFi.com and www.PURbiologics.com.